9,900% 0.000099

Syros Pharmaceuticals Inc (SYRS)

개요 뉴스 가격 이력 옵션 체인 Financials 토론 예측 주식 분할

Syros Pharmaceuticals Inc 주식(SYRS)의 최신 뉴스

Syros Pharmaceuticals Inc (SYRS)

Syros Pharmaceuticals Inc 주식(SYRS)의 최신 뉴스

MSN Money - MSN

Syros Pharmaceuticals stock (US8719201096): Latest updates and business overview - AD HOC NEWS

Syros Pharmaceuticals Inc (OTCM:SYRS) Stock Earnings Transcripts - GuruFocus

Syros Pharmaceuticals Inc (OTCM:SYRS) Stock Price & 30 Year Financial Data - GuruFocus

Syros Pharmaceuticals stock (US8719201096): Delisting to OTC triggers investor attention - AD HOC NEWS

Acute Myeloid Leukemia Market: Rapid Increment Driven by Innovation by 2034 – DelveInsight | SystImmune, Jasper Therapeutics, Chimerix, Akeso Biopharma, Syros Pharma, TC Biopharm - Barchart.com

hVIVO plc (OPORF) Analyst insights, Price targets and Recommendations - Yahoo Finance Singapore

Syros Pharmaceuticals, Inc. (0LC7.L) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada

Stock List: Research Stocks from Around the World - GuruFocus

Polaris Management Co VII L L C Net WorthInsider Trades and Bio as of Apr 21, 2026 - Benzinga

Syros Pharmaceuticals (SYRS) Expected to Announce Quarterly Earnings on Wednesday - Defense World

MSN - MSN

Myelodysplastic Syndrome Clinical Trial Pipeline Accelerates as 120+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight - The Globe and Mail

Syros to delist from Nasdaq, deregister from SEC - MSN

AKPKD Pipeline 2025: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight | AceLink Therapeutics, Sanofi, DiNAQOR AG, Poxel, AceLink Therapeutics, Regulus Therapeut - The Globe and Mail

Myelodysplastic Syndrome Pipeline Analysis, 2025 by DelveInsight | Novartis, Syros Pharmaceuticals, Curis, Ryvu Therapeutics, Chia Tai Tianqing Pharmaceutical Group, Amgen, Sanofi, Forma Therapeutics, - Barchart.com

Quetzal Therapeutics Debuts with Expert Leadership, High-Impact Pipeline and $50 Million of Committed Capital - Yahoo Finance

Syros Pharmaceuticals (SYRS) FDA Approvals, PDUFA Dates & Drug Alerts 2025 - MarketBeat

Syros Pharmaceuticals(SYRS) Stock Options Chain | Quotes & News - Moomoo

SYROS PHARMACEUTICALS Earnings Preview: Recent $SYRS Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative

Shareholders that lost money on Syros Pharmaceuticals, Inc.(SYRS) should contact Levi & Korsinsky about Securities Fraud InvestigationSYRS - ACCESS Newswire

SYRS Stock Price, News & Analysis - Stock Titan

Rege Nephro Acquires Tamibarotene Assets from Syros Pharmaceuticals to Advance ADPKD Program - BioPharma APAC

Rege Nephro Acquires Tamibarotene-Related Assets from Syros Pharmaceuticals for U.S. Clinical Trials - PR Newswire

Syros Pharma pulls out of deal with RaQualia - The Pharma Letter

SYRS Stock Price and Chart — OTC:SYRS - TradingView

Syros Pharmaceuticals, Inc.Common Stock (NQ: SYRS - FinancialContent

Finance Watch: Sutro Halves Workforce, Cuts Lead ADC And CEO Moves On - Citeline News & Insights

Syros Pharmaceuticals | EFFECT: Others - Moomoo

Wondering what's happening in today's after-hours session? - ChartMill

Syros Pharmaceuticals settles debt with Oxford Finance - Investing.com

Why US Stock Futures Are Rising TodayInvesco QQQ Trust, Series 1 (NASDAQ:QQQ), State Street SPDR S&P 500 ETF Trust (ARCA:SPY) - Benzinga

Failed Clinical Trial Forces Syros Pharmaceuticals Into Delisting and Wind-Down Operations - Stock Titan

Syros Pharmaceuticals stock hits 52-week low at $0.18 amid steep decline - MSN

Syros Pharmaceuticals stock plunges to 52-week low of $0.16 - Investing.com

Bronstein, Gewirtz and Grossman, LLC Encourages Syros Pharmaceuticals, Inc. (SYRS) Investors to Inquire about Securities Investigation - ACCESS Newswire

Odyssey hires Jason Haas as CFO - BioCentury

Syros Pharmaceuticals faces Nasdaq delisting risk - Investing.com

BlossomHill Therapeutics Appoints Geoff Oxnard, M.D., as Chief Medical Officer and Executive Vice President - Business Wire

Syros Pharmaceuticals' SWOT analysis: stock faces challenges after trial setback - Investing.com Australia

Syros Pharmaceuticals CEO Chee Conley sells shares worth $26,932 - Investing.com

Syros Pharmaceuticals announces major company changes - Investing.com

Avidity Partners Management LP's Strategic Acquisition in Syros Pharmaceuticals Inc - GuruFocus

Syros Stock Plunges as Lead Cancer Study Fails to Meet Primary Goal - Yahoo Finance

Syros’s Hopes Dashed As Tamibarotene Flunks Phase III MDS Trial - Citeline News & Insights

TD Cowen Downgrades Syros Pharmaceuticals(SYRS.US) to Hold Rating - Moomoo

SYRS과 유사한 종목